Home Contact Us Search Toxic Exposure Study Trust Foundation

Thimerosal Content

Mercury Amalgam Thimerosal Founders Donations

Thimerosal Toxicity
Neurotoxicity
Thimerosal Content
Published  Studies
Thimerosal Vs. Hg(II)
Vaccine Hg Exposure
FDA Hypocracy
Experts Speak Out
Vaccines & Development
IOM Conference
Neurodevelopmental Effects
Autism & Mercury
Thimerosal Links
Mothering & Autism
Homeland Insecurity
Records Sealed
Government Knew
Known Effects
Vaccine Lawsuits
Eli Lilly & Thimerosal
Vaccine Booster
Hg Free Vaccines
Vaccine Assessment
Metals & Autism
Congressional Acts
WHO & Thimerosal
Flu Vaccines
Autism & Vaccines
Autism & Detoxification
Childhood Immunizations
Aluminum & Vaccines
Vaccine Adjuvants
Allergic Components
Thimerosal & Autism
AAPS Opposition
Toxic Vaccines
Mercury Exposure
Hg in Medicines
Vaccines-Pro & Con
Candida & Autism
Thimerosal Effects
Gulf War Syndrome
Dr. Synder Responds
Myth From Reality
Vaccine History
Developmental Disorders
CDC's NIP
Polio Vaccine
Smallpox
Chickenpox
Safe Minds
Why So Long?
1st Vaccine Conference
2nd Vaccine Conference
Vaccine Injury
MMR and IBD

Thimerosal Content in Some US Licensed Vaccines 


From the Vaccine Safety Institute (http://www.vaccinesafety.edu/thi-table.htm)

Vaccine

Brand Name Manufacturer

Thimerosal Concentration1

Mercury ug/0.5 ml pg in 2000 PDR pg in 1999 PDR
Anthrax Anthrax vaccine BioPort Corporation

   0   

   0   

DTaP

 

Acel-Imune
Tripedia
Certiva
Infanrix
Lederle Laboratories
Pasteur Merieux Connaught
North American Vaccine
SmithKline Beecham

.01%
.01%
.01%
   0   

25
25
25
   0   

1524
2307
1986
3010

1510
2340
1972
3061

DTwP All Products

.01%

25

DT All Products

.01%

25

Td All Products

.01%

25

TT All Products

.01%

25

DTwP-Hib Tetramune Lederle Laboratories

.01%

25

1550

1544

Hib

ActHIB
ProHIBiT(4)
TriHIBit
HibTITER       multi-dose
                    single dose
PedvaxHIB liquid(2)
COMVAX(3)
Omni HIB

Pasteur Merieux Connaught
Pasteur Merieux Connaught
Pasteur Merieux Connaught
Lederle Laboratories
Lederle Laboratories
Merck
Merck
SmithKline Beecham

   0   
.01%
.01%
.01%
   0   
   0   
   0   
   0   

   0   
25
25
25
   0   
   0   
   0   
   0   

2283
-
-
1531
1531
1850
1760
3022

2316
2345
2340
1520
1520
1853
1750
3072

Hepatitis A Havrix
Vaqta adult/pediatric
SmithKline Beecham
Merck

   0   
   0   

    0   
   0   

3004
1899

3056
1906

Hepatitis B Engerix-B
Engerix-B preservative free
Recombivax HB
Recombivax HB preservative free
SmithKline Beecham
SmithKline Beecham
Merck
Merck

.005%
--
.005%
   0   

12.5
.05*
12.5
   0   

2997
--
1880
1880

3048
--
--
1883

Influenza All products

.01%

25

IPV IPOL Pasteur Merieux Connaught

   0   

   0   

2300

2333

Lyme LYMErix SmithKline Beecham

   0   

   0   

3019

Web

Meningococcal Menomune A, C, AC and A/C/Y/W-135 CLI

.01%

25

2305

2339

MMR MMR-II Merck

   0   

   0   

1819

1819

OPV Orimune Lederle Laboratories

   0   

   0   

1528

Pneumococcal Prevnar
Pnu-Imune 23
Pneumovax 23
Wyeth-Lederle Vaccines
Lederle Laboratories
Merck

   0   
.01%
   0   

   0   
25
   0   


1541
1858

1533
1860
Rabies

 

Rabies Vaccine Adsorbed
RabAvert
IMOVAX
Bioport Corporation
Chiron
Pasteur Merieux Connaught

.01%
   0   
   0   

25
   0   
   0   

3033
941
2296

--
898
2329

Rotavirus Rotashield Wyeth-Ayerst

   0   

   0   

3314

Typhoid Vivotef Ty21a Berna

   0   

   0   

766

727

Typhoid Fever Typhim Vi
Typhoid vaccine
Pasteur Merieux Connaught
Wyeth-Ayerst

   0   
   0   

   0   
   0   

2313
3336

2348
3399

Varicella Varivax Merck

   0   

   0   

1901

1908

Yellow Fever YF-Vax Pasteur Merieux Connaught

   0   

   0   

 

2350

1.    A concentration of 1:10,000 is equivalent to a 0.01% concentration. Thimerosal is approximately 50% Hg by  weight.   A 1:10,000 concentration contains 25 micrograms of Hg per 0.5 mL.

vacthimcontent.gif (4288 bytes)

2. A previously marketed lyophilized preparation contained .05% thimerosal.

3. COMVAX is not approved for use under 6 weeks of age because of decreased response to the Hib component.

4. ProHIBit is recommended by the Academy only for children 12 months of age and older.

*. The new Engerix-B product contains only trace amounts of thimerosal (<1 mcg)

 

Testimony of

Coleen Boyle, Ph.D.
Acting Associate Director for Science and Public Health
National Center on Birth Defects and Development Disabilities
Centers for Disease Control and Prevention (CDC)

Before the Committee on Government Reform
U. S. House of Representatives
April 26, 2001

http://www.cdc.gov/washington/legislative/04262001.htm

 

Thimerosal

Despite the fact that thimerosal preservative has been effective in lowering the risk that vaccines could be contaminated by bacteria leading to serious infection, the United States Public Health Service agencies, including NIH, FDA, HRSA, and CDC, working collaboratively with the American Academy of Pediatrics and the American Academy of Family Physicians, took action in mid-1999 to begin removing thimerosal preservative from the vaccine supply. While the risk of harm from this source was only theoretical, the decision was made as a precautionary measure. The elimination of thimerosal preservative from vaccines was judged a feasible means of reducing an infant’s total exposure to mercury in a world where other environmental sources of exposure may be more difficult or impossible to eliminate.

As a result of this action, all manufacturers of routinely recommended licensed pediatric vaccines are now producing for the U.S. market only vaccines that are thimerosal-free or contain trace amounts of thimerosal. The vaccines are supplied in single-dose vials which eliminates the need for a preservative.

 


Testimony of

Roger H. Bernier, Ph.D., M.P.H.
Associate Director for Science
National Immunization Program
Centers for Disease Control and Prevention

Before the Committee on Government Reform
U.S. House of Representatives
July 18, 2000

http://www.cdc.gov/washington/legislative/07182000.htm

The United States has been a world leader in the development and licensing of new vaccines and has placed a high priority on producing vaccines which meet the highest standards for safety and efficacy. These standards pertain not only to the active ingredients, which elicit protective immune responses, but also to the preservatives such as thimerosal. Thimerosal, an ethylmercury containing preservative used since the 1930's, is added to some vaccines because it is very effective in preventing bacterial contamination and resulting infections in vaccine recipients.

In mid-1999 administration of a combination of vaccines that contained thimerosal as a preservative was recognized as exceeding one federal guideline for mercury exposure. It is important to note that the form of mercury used in thimerosal is ethylmercury. Although toxicity data are lacking for ethylmercury, it is currently assumed that methylmercury guidelines are appropriate to use in this situation. Even though there was no evidence of possible harm caused by ethylmercury exposure from immunizations, the United States Public Health Service agencies, including NIH, FDA, HRSA, and CDC took action, working collaboratively with the American Academy of Pediatrics and the American Academy of Family Physicians. Last summer a goal was set for the removal or significant reduction of thimerosal as a preservative from all vaccines routinely administered to children in the first year of life. While the risk of harm from this source was only theoretical, the decision to set a goal to remove thimerosal was made as a precautionary measure. Given the concern about the health effects of mercury of any sort, the elimination of mercury from vaccines was judged a feasible means of reducing an infant's total exposure to mercury in a world where other environmental sources of exposure may be more difficult or impossible to eliminate.

During the year since the goal was set, progress in removing or reducing thimerosal in vaccines has been outstanding. The United States has now achieved a pediatric hepatitis B vaccine supply from two manufacturers that is free of thimerosal as a preservative, and, as of this month, a Haemophilus influenzae type b vaccine supply from all four manufacturers is available that is free of thimerosal as a preservative. For DTaP vaccines, there are four manufacturers, one of which has produced a vaccine that is already free of thimerosal, and at least one other is expected to produce a vaccine without thimerosal as a preservative within six to nine months. Measles, mumps, rubella, varicella, inactivated polio, and the recently licensed conjugate pneumococcal vaccines have never contained thimerosal. Based on our progress over the past year, the maximum amount of mercury an infant may be exposed to from routine immunizations has been reduced by 60 percent.

Thus, by early 2001, the United States is expected to have obtained an adequate vaccine supply for the routine pediatric vaccines that is completely free of thimerosal as a preservative.

 

 

Back Home Up Next